Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) GlobeNewswire October 22, 2025 ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and significant unmet medical need Electra has initiated the SURPASS global pivotal trial evaluating […]

Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer GlobeNewswire October 22, 2025 Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH) Financing will also support indication expansion of ELA026 in hematologic cancers and

Electra Therapeutics Announces First Patients Dosed in the SURPASS Phase 2/3 Pivotal Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) GlobeNewswire October 22, 2025 The SURPASS study is enrolling patients at research sites across the U.S. and Europe ELA026 targets signal regulatory proteins (SIRP) as a novel approach to treating the life-threatening hyperinflammatory pathology of

Stifel Reports Third Quarter 2025 Results GlobeNewswire October 22, 2025 ST. LOUIS, Mo., Oct. 22, 2025 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today reported net revenues of $1.4 billion for the three months ended September 30, 2025, compared with $1.2 billion a year ago. Net income available to common shareholders was $202.1 million,

Troilus Announces Change of Auditor GlobeNewswire October 22, 2025 MONTREAL, Oct. 22, 2025 (GLOBE NEWSWIRE) — Troilus Gold Corp. (TSX: TLG; OTCQX: CHXMF; FSE: CM5R) (“Troilus” or the “Company”) announces that it has changed its auditor from McGovern Hurley LLP (“Former Auditor”) to Deloitte LLP (“Successor Auditor” or “Deloitte LLP”) effective October 21, 2025. The

Enthusiast Gaming Provides Update Regarding Annual General and Special Meeting of Shareholders GlobeNewswire October 22, 2025 TORONTO, Oct. 22, 2025 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading digital publisher focused on building tools, platforms, and experiences for gamers, wishes to provide an update to shareholders regarding

Bluwhale Secures $10 Million Strategic Series A in Institutional Funding Large Institutions See Potential of AI Agents on Blockchains Delivering Personalized Financial Services to Millions of Consumers GlobeNewswire October 22, 2025 SAN FRANCISCO , Oct. 22, 2025 (GLOBE NEWSWIRE) — Bluwhale, the decentralized AI network powering agents on blockchains, today announced the close of its

Mercury Awarded Contract To Develop Multi-Mission Subsystem for U.S. Military Programs GlobeNewswire October 22, 2025 ANDOVER, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a global technology company that delivers mission-critical processing to the edge, today announced it was awarded a multi-year, cost-plus-fixed-fee development contract in September to develop a

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital GlobeNewswire October 22, 2025 FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix's investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficiency (AVP-D) The trial is intended to generate

Vema Hydrogen to Help Power California's Clean Energy Transition as a Qualified FPH2 Supplier Vema Hydrogen Recognized as a Qualified Supplier by the First Public Hydrogen Authority GlobeNewswire October 22, 2025 LOS ANGELES, Oct. 22, 2025 (GLOBE NEWSWIRE) — Today, Vema Hydrogen, developer of a disruptive renewable hydrogen production technology – Engineered Mineral Hydrogen(TM) –